Literature DB >> 19349601

Adverse antiepileptic drug effects: toward a clinically and neurobiologically relevant taxonomy.

Piero Perucca1, Jewell Carter, Victoria Vahle, Frank G Gilliam.   

Abstract

BACKGROUND: Adverse effects (AEs) of antiepileptic drugs (AEDs) are a major impediment to optimal dosing for seizure control. Better understanding of clinical properties of AEs is a prerequisite for systematic research of their neurobiological underpinnings. This study aimed to define specific patterns of AE occurrence and determine their clinical relevance based on their association with subjective health status.
METHODS: Two hundred subjects with epilepsy completed validated self-report health assessments, including the Adverse Event Profile (AEP) and Quality of Life in Epilepsy Inventory (QOLIE)-89. Factor analysis was performed on the 19 AEP items to identify distinct classes of AEs. Correlations between AE class scores and QOLIE-89 scores were evaluated. Multivariate analysis was used to assess contributions of AE class scores to QOLIE-89 scores after controlling for depression and seizure frequency. Relationships between changes in AE class scores and changes in QOLIE-89 scores were also investigated in a subgroup of 62 subjects enrolled in a randomized trial.
RESULTS: The mean number of AEs per subject was 6.5. AEs were segregated into five classes: Cognition/Coordination, Mood/Emotion, Sleep, Weight/Cephalgia, and Tegument/Mucosa. Higher scores in each AE class were associated with lower QOLIE-89 scores. Cognition/Coordination scores were the strongest predictor of QOLIE-89 scores. Improvements in Cognition/Coordination, Mood/Emotion, and Tegument/Mucosa scores were associated with improvements in QOLIE-89 scores. Improved Cognition/Coordination was the only predictor of improved QOLIE-89.
CONCLUSION: Adverse effects (AEs) of antiepileptic drugs can be classified in five biologically plausible factors. When specific classes of AEs are identified and attempts are made to reduce them, quality of life is significantly improved.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19349601      PMCID: PMC2677485          DOI: 10.1212/01.wnl.0000345667.45642.61

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  30 in total

1.  Inhibition of rostral basal forebrain neurons promotes wakefulness and induces FOS in orexin neurons.

Authors:  Shinsuke Satoh; Hitoshi Matsumura; Tomoko Nakajima; Ken-ichi Nakahama; Tuyoshi Kanbayashi; Seiji Nishino; Hiroshi Yoneda; Yasufumi Shigeyoshi
Journal:  Eur J Neurosci       Date:  2003-04       Impact factor: 3.386

Review 2.  The neurobiology of sleep: genetics, cellular physiology and subcortical networks.

Authors:  Edward F Pace-Schott; J Allan Hobson
Journal:  Nat Rev Neurosci       Date:  2002-08       Impact factor: 34.870

3.  Association of multidrug resistance in epilepsy with a polymorphism in the drug-transporter gene ABCB1.

Authors:  Asra Siddiqui; Reinhold Kerb; Michael E Weale; Ulrich Brinkmann; Alice Smith; David B Goldstein; Nicholas W Wood; Sanjay M Sisodiya
Journal:  N Engl J Med       Date:  2003-04-10       Impact factor: 91.245

4.  Levetiracetam for partial seizures: results of a double-blind, randomized clinical trial.

Authors:  J J Cereghino; V Biton; B Abou-Khalil; F Dreifuss; L J Gauer; I Leppik
Journal:  Neurology       Date:  2000-07-25       Impact factor: 9.910

5.  Genetic ablation of orexin neurons in mice results in narcolepsy, hypophagia, and obesity.

Authors:  J Hara; C T Beuckmann; T Nambu; J T Willie; R M Chemelli; C M Sinton; F Sugiyama; K Yagami; K Goto; M Yanagisawa; T Sakurai
Journal:  Neuron       Date:  2001-05       Impact factor: 17.173

6.  Early identification of refractory epilepsy.

Authors:  P Kwan; M J Brodie
Journal:  N Engl J Med       Date:  2000-02-03       Impact factor: 91.245

7.  A randomized, controlled trial of surgery for temporal-lobe epilepsy.

Authors:  S Wiebe; W T Blume; J P Girvin; M Eliasziw
Journal:  N Engl J Med       Date:  2001-08-02       Impact factor: 91.245

Review 8.  Optimizing health outcomes in active epilepsy.

Authors:  Frank Gilliam
Journal:  Neurology       Date:  2002-04-23       Impact factor: 9.910

9.  Safety of divalproex sodium in migraine prophylaxis: an open-label, long-term study. Long-term Safety of Depakote in Headache Prophylaxis Study Group.

Authors:  S D Silberstein; S D Collins
Journal:  Headache       Date:  1999-10       Impact factor: 5.887

Review 10.  Bodyweight gain and anticonvulsants: a comparative review.

Authors:  P Jallon; F Picard
Journal:  Drug Saf       Date:  2001       Impact factor: 5.228

View more
  34 in total

1.  Polysomnographic assessment of sleep disturbances in children with developmental disabilities and seizures.

Authors:  Silvia Miano; Oliviero Bruni; Debora Aricò; Maurizio Elia; Raffaele Ferri
Journal:  Neurol Sci       Date:  2010-05-27       Impact factor: 3.307

2.  Adverse antiepileptic drug effects.

Authors:  Warren T Blume
Journal:  Epilepsy Curr       Date:  2010-01       Impact factor: 7.500

3.  Adverse Cutaneous Drug Reactions Associated with Old- and New- Generation Antiepileptic Drugs Using the Japanese Pharmacovigilance Database.

Authors:  Keiko Hosohata; Ayaka Inada; Saki Oyama; Iku Niinomi; Tomohito Wakabayashi; Kazunori Iwanaga
Journal:  Clin Drug Investig       Date:  2019-04       Impact factor: 2.859

4.  Baseline psychiatric evaluations are needed to treat seizures.

Authors:  Rochelle Caplan
Journal:  Epilepsy Curr       Date:  2012-11       Impact factor: 7.500

5.  Early Detection of Human Epileptic Seizures Based on Intracortical Microelectrode Array Signals.

Authors:  Yun S Park; G Rees Cosgrove; Joseph R Madsen; Emad N Eskandar; Leigh R Hochberg; Sydney S Cash; Wilson Truccolo
Journal:  IEEE Trans Biomed Eng       Date:  2019-06-06       Impact factor: 4.538

6.  Potentiating α2 subunit containing perisomatic GABAA receptors protects against seizures in a mouse model of Dravet syndrome.

Authors:  Toshihiro Nomura; Nicole A Hawkins; Jennifer A Kearney; Alfred L George; Anis Contractor
Journal:  J Physiol       Date:  2019-05-20       Impact factor: 5.182

7.  Epilepsy and quality of life: what does really matter?

Authors:  Mario Tombini; Giovanni Assenza; Livia Quintiliani; Lorenzo Ricci; Jacopo Lanzone; Vincenzo Di Lazzaro
Journal:  Neurol Sci       Date:  2021-01-15       Impact factor: 3.307

8.  A Trial of Sertraline or Cognitive Behavior Therapy for Depression in Epilepsy.

Authors:  Frank G Gilliam; Kevin J Black; Jewell Carter; Kenneth E Freedland; Yvette I Sheline; Wei-Yann Tsai; Patrick J Lustman
Journal:  Ann Neurol       Date:  2019-08-15       Impact factor: 10.422

9.  Neuro-QOL and the NIH Toolbox: implications for epilepsy.

Authors:  Cindy J Nowinski; David Victorson; Jose E Cavazos; Richard Gershon; David Cella
Journal:  Therapy       Date:  2010-09-01

10.  Tolerability of Antiseizure Medications in Individuals With Newly Diagnosed Epilepsy.

Authors:  Bshra Ali A Alsfouk; Martin J Brodie; Matthew Walters; Patrick Kwan; Zhibin Chen
Journal:  JAMA Neurol       Date:  2020-05-01       Impact factor: 18.302

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.